Biotherapeutics News and Research

RSS

New research explains why some cancers don't respond to immunotherapy

New research has uncovered a mechanism thought to explain why some cancers don't respond to a widely used form of immunotherapy called "checkpoint inhibitors" or anti-PD-1.

6 Aug 2019

IONTAS and Teva Pharmaceuticals announce new antibody optimization agreement

IONTAS Limited, a leader in antibody discovery and optimization of human monoclonal antibody libraries, today announced an agreement with Teva Pharmaceuticals (Teva) to apply its technologies and know-how to the optimization of human antibodies for use as biotherapeutics.

From FairJourney Biologics 31 Jul 2019

Novel therapeutic strategy for treating Lafora Disease shows promise in preclinical study

A team of scientists have designed and tested in mice a novel and promising therapeutic strategy for treating Lafora Disease, a fatal form of childhood epilepsy.

25 Jul 2019

Researchers completely eliminate all traces of HIV from infected mice

For the first time, researchers have successfully removed HIV-1 DNA from the genomes of living animals, a critical step towards a potential cure for the disease.

4 Jul 2019

Using Light Scattering to Characterize Protein-Nucleic Acid Interactions

Harnessing the interactions between DNA, RNA, and proteins holds much promise for detecting biomarkers, diagnosing disease, and improving cancer-targeting therapeutics. Quantifying these interactions is essential for understanding and controlling their biomolecular mechanisms.

From Waters | Wyatt Technology 26 Jun 2019

Stability Testing of Therapeutic Proteins using DLS and Machine Learning

PIPPI scientists from different fields are developing methodologies, tools, and databases to guide the rational formulation of robust protein-based therapeutics. Their overall goal is to develop a database to guide product formulation development.

From Waters | Wyatt Technology 26 Jun 2019

CityU scientist receives grant for new way to cultivate 10 distinct probiotic bacteria

An environmental scientist at City University of Hong Kong has been awarded US$100,000 by Grand Challenges Explorations, an initiative of the Bill & Melinda Gates Foundation, for a novel way to cultivate 10 distinct probiotic bacteria simultaneously.

20 Jun 2019

Bruker launches timsTOF fleX with ESI/MALDI capability for SpatialOMx at ASMS 2019

Bruker Daltonics has launched a novel timsTOF fleX mass spectrometer which combines ESI/MALDI capability for SpatialOMx on a single instrument.

From Bruker Daltonics 10 Jun 2019

Sartorius Stedim Biotech launches new SIMCA 16 software for multivariate data analytics

Sartorius Stedim Biotech, a leading international partner of the biopharmaceutical industry today announced the new SIMCA® 16 software for multivariate data analytics is available from its subsidiary Sartorius Stedim Data Analytics.

From Sartorius 9 May 2019

Sartorius Stedim Biotech introduces new ambr 15 cell culture microbioreactor system

Sartorius Stedim Biotech, a leading international partner of the biopharmaceutical industry, is introducing its new generation of ambr 15 cell culture automated microbioreactor system.

From Sartorius 3 May 2019

Celltrion and iProgen Biotech announce partnership for development of novel ADCs

On April 8, Celltrion and the Canada-based iProgen Biotech Inc. announced to agree to partner for the development of novel ADCs against validated antibody targets, including HER2 and CD20.

8 Apr 2019

Probing Submicron Protein Aggregation using Asymmetrical Flow Field-Flow Fractionation, AF4, and Light Scattering

The most recent developments by Wyatt in their instrumentation and software have made the full potential of FFF accessible to a wider user base. In this interview, Kim R. Williams and Christoph Johann talk to News-Medical and Life Sciences about the technologies and their research.

From Waters | Wyatt Technology 27 Mar 2019

Injection of genetically modified virus effectively treats metastatic melanoma patients

Injection of a genetically modified virus that induces the body's own immune cells to attack metastatic melanoma effectively treated almost 40 percent of patients with tumors that could not be surgically removed, according to researchers from three prominent cancer centers in a study published as an "article in press" on the Journal of the American College of Surgeons website in advance of print publication.

28 Jan 2019

RBSC announces partnership with Mitacs to develop and test yeast-based RNAi technology

Renaissance BioScience Corp., a leading global microorganism bioengineering company, is pleased to announce a new partnership with Mitacs, the University of British Columbia and the University of Manitoba for a three-year, Cdn$975,000 multi-investigator research and development project.

24 Jan 2019

Bio-Rad publishes new paper on generation, characterization of complex-specific antibodies

Bio-Rad Laboratories, Inc., a global leader of life science research and clinical diagnostic products, has published new findings on the generation and characterization of drug-target complex-specific antibodies for pharmacokinetic analysis of biotherapeutics.

From Bio-Rad Laboratories 11 Jan 2019

High-performing MS device reaches new level in characterizing protein impurities

In response to current regulatory guidance a Mass Spectrometry-based Host Cell Protein detection approach with faster, more accurate and wider-ranging detection is essential.

10 Jan 2019

MD Anderson Cancer Center and 4D pharma team up to evaluate live biotherapeutic oncology pipeline

The University of Texas MD Anderson Cancer Center and 4D pharma today announced a strategic collaboration to evaluate 4D's live biotherapeutic oncology pipeline across a range of cancer settings.

7 Jan 2019

Stand Up to Cancer supports potential approach to more efficiently target pancreatic cancer

Research on a new way of deploying the immune system against pancreatic cancer, an exceptionally lethal cancer that has so far resisted new immunotherapies, will receive $1 million in initial funding from Stand Up to Cancer.

21 Nov 2018

Forbius initiates Phase 2a trial evaluating efficacy, safety of AVID100 in patients with squamous NSCLC

Forbius, a clinical stage company developing biotherapeutics targeting EGFR and TGF-β pathways, today announced that the first patient has been dosed in a Phase 2a trial evaluating the efficacy and safety of AVID100 in patients with squamous non-small cell lung cancer whose tumors overexpress epidermal growth factor receptor.

23 Oct 2018

LineaRx signs agreement with Takis/Evvivax to develop linear-DNA based anti-cancer vaccines

Applied DNA Sciences Inc. announced today that LineaRx, Inc., its wholly-owned subsidiary focused on next-generation biotherapeutics, has signed a Joint Development Agreement with Takis S.R.L. and Evvivax S.R.L., biotechnology companies focused on the discovery and development of DNA based anti-cancer vaccines for the human and animal markets, respectively.

20 Sep 2018